Life Sciences Alternative Funding United States

Life Sciences Alternative Funding (LSAF) founded in 213 is a direct investment firm based in White Plains New York. The firm focuses exclusively on providing debt capital for commercial-stage medical technology companies. The firm can allocate between USD 1M-5M per investment. The firm looks to provide flexible ?tailor-made? financing solution to companies. The firm can invest globally and is currently seeking new investment opportunities.

Steve DeNelsky
President 

Lilly Asia Ventures China

Lilly Asia Ventures is the venture capital arm of Eli Lilly that focuses on investments in the life sciences in Asia, particularly China. The firm was established in 2008 and is based in Shanghai, China. The firm is stage agnostic; investing in early, growth, and up to pre-IPO opportunities. The firm’s investment size is USD 5-20 million per company. The firm primarily invests in companies in China, but is open to companies across Asia-Pacific as long as there is some sort of China angle. The firm is actively seeking new investment opportunities.

Lilly Asia Ventures primarily focuses on therapeutics but is also interested in medical devices, diagnostics, animal health, and biotech other. The firm is most interested in products that will have a significant impact on medical care in China. For therapeutics, the firm seeks best-in-class or first-in-class products. The firm is opportunistic to the indication and the phase of development and will consider products in pre-clinical up to NDA. Historically, the firm invests in therapeutics for oncology, inflammatory diseases, and metabolic disorders.

Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Judith Li
Principal 
Michael Zhang
Investment Manager 

Longitude Capital United States

Longitude Capital is a private equity group founded in 2006 with offices in Menlo Park, California and Greenwich, Connecticut. The firm has $700 million in assets and has raised two funds, with the most recent fund closing at $385m in 2012. Longitude makes both venture-stage and growth-stage equity investments, which are typically in the $10-30 million range. Longitude Capital primarily invests in North America and the European Union but may also consider opportunities in the Middle East.

Year Founded
2006
Investor Type
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Mark Chin

Lumira Capital

Lumira Capital is a Venture Capital firm that changed its name from MDS Capital In 2007 and have been investing in companies since 1989. The firm is based in Toronto will additional offices in Boston and Montreal. The firm currently manages 2 funds for a total of approximately $180 million in assets under management. The firm’s Lumira Capital II fund currently hold approximately $115 million in assets and is looking to invest in companies across North America. The firms Merck Lumira Biosciences fund formed via a partnership with Merck Serano, currently holds around $65 million in assets and is looking for early stage opportunities in companies located in or looking to move to Quebec. The firm typically makes initial investments ranging from $2-$5 million of equity and looks to invest $8-$12 million over the lifetime of the investment. The firm plans to make 4-6 investments over the next 6-9 months.

Investor Type
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Peter Van Der Velden
Managing General Partner 
Jacki Jenuth
Vice President 
Brian Underdown
Managing Partner 
Beni Rovinski
Managing Partner 

Lymo Investments

Lymo Investments is a multi-family venture fund based in Silicon Valley, CA. The firm is an active investor in the medical device sector, and is interested in opportunities worldwide. Initial investments are typically about $50,000 with the potential for follow-on investments totaling $500,000, and may be structured as equity or as debt. Lymo Ventures does not invest in seed rounds. In the recent past Lymo Investments has allocated new investments at a rate of approximately one every two months. The firm offers support and expertise to portfolio companies but does not seek a board seat.

Norm Gitis
Founder 

M.H. Carnegie & Co.

M.H. Carnegie & Co. founded in 21 is a venture capital and private equity firm based in Sydney Australia. The currently has about $2 million in committed capital across several funds. The firm invests in several sectors including the Life Sciences. The firm can make early to late stage investments typically allocating USD 2-5 million per company. The firm is currently interested in companies abroad that plan to set up operations in Australia as the firm is mandated to invest in Australian-based companies. The firm plans to make 2-3 new investments in the next 12 months and is actively seeking new opportunities.
Mark Carnegie
Principle 
Trevor Moody
Principle 

Marvao Medical Devices Ireland

Marvao Medical is an early stage medical device company founded in 2006 to develop and commercialize products that reduce the incidence of catheter related bloodstream infections. Our first 2 product lines target a $1B global market opportunity. The first product line is now FDA cleared and is being evaluated at 3 centers in the US with very positive results. We are seeking to raise funds in mid/late 2015 to support full commercialization of this product which will enable the company to become highly profitable in early 2017.

 

Year Founded
2006
Medtech Subsector
Indication
Medtech Phase of Development
Technology Overview
We have developed a technology platform that aims to reduce the risk of catheter related bloodstream infections (CRBSI) in patients who require long term vascular access. We have received FDA clearance for our first commercial application of this platform, a hemodialysis (HD) catheter, which is now being clinically evaluated at 3 centres in the US. Our next commercial application is a line of central venous catheters used to deliver chemotherapy, antibiotics, nutrition, and hydration. The overall global opportunity for these two applications is >$1B.
Alliance & Collaborations
In 2008 we entered into a strategic OEM partnership with Harmac Medical Products. Harmac has major manufacturing facilities in the US, Ireland, and Mexico. They have supported our product development programs (including our FDA applications), built our clinical evaluation product, and are now well positioned to rapidly scale up production in 2015.
Supporting Metrics or Evidence
Clinically reported CRBSI rates for HD catheters range between 1.6 and 5.5 events/1000 catheter days. Our HD catheter clinical evaluation has accumulated 3000 catheter days to date with only 1 reported CRBSI event, yielding a rate of 0.3/1000 catheter days. These results have attracted significant interest from healthcare providers who recognise our product's potential to help deliver significantly better care at lower cost within their centers.
Current Financing Needs
Marvao is fully funded to meet our product development and clinical evaluation milestones in 2015. We are looking for new investors to come in alongside our existing investors in Q3 2015 to support our 2016 commercialization program. Our financial model indicates that a quantum of $2.0 - $2.5M is needed to enable the company to become profitable in early 2017.
Current Timeline
In January 2015 we will start the 2nd phase of our clinical evaluation by working directly with one of the world’s two largest HD service providers. The objective is to measure CRBSI rates over 10,000 catheter days across multiple centres in their network. This company is also the market’s single largest purchaser of HD catheters. We expect that low CRBSI rates observed over the course of this evaluation will translate into a significant catheter supply agreement in 2016.
IP Status
Our core technology is currently protected by 4 issued US patents, with 4 additional applications underway. We are in the process of further expanding this portfolio to cover commercially critical product features beyond our core technology.
Recent Milestones
Passed our 2nd FDA QSIT audit in Q3 2014. Passed our annual ISO 13485 certification audit in Q3 2014. Third HD catheter 510k clearance obtained from the FDA in Q4 2014
Management Team Highlights
Eamonn Hobbs: Chairman of the Board. Mark Saab: Co Founder, Principal Investor, Non Executive Director. Chris Davey: Co Founder, CEO
Chris Davey
CEO 

Mayo Clinic Ventures

Mayo Clinic Ventures serves to commercialize Mayo Clinic technologies for the benefit of patients worldwide while generating revenue to support clinical practice, research and education at Mayo Clinic. The office has licensed hundreds of technologies in the fields of medical devices, diagnostics, therapeutics, and healthcare IT, and has focused efforts in technology-based ventures and start-ups.  Mayo Clinic Ventures also has a $20M venture capital fund which is used to spin out companies that are developing products based on Mayo Clinic research.

Kelly Krajnik
Business Development Manager 

MBL Venture Capital

MBL Venture Capital founded in 2 is the investment arm of Medical & Biological Laboratories Co. a Japanese biotechnology company and is based in Nagoya Japan with an additional office in Tokyo. The firm primarily makes early stage investments solely in the Life Sciences. The firm recently raised a new fund in March 214 and looks to make about 2-3 new investments in the next 12 months. The firm typically allocates USD 1-2 million per round and up to USD 3 million per company. The firm can invest globally with particular interests in the USA and Europe. The firm is actively seeking new investment opportunities.
Masako Hashimoto
Senior Manager